

AMICUS SIGNS CO-PROMOTION CONTRACTS WITH GLAXOSMITHKLINE (GSK) FOR BOSNIA AND SERBIA

PRESS RELEASE NO. 18: AMICUS SIGNS CO-PROMOTION AGREEMENT WITH GSK

Amicus' Bosnian and Serbian affiliates signed co-promotion agreements with GSK. The two agreements provide for Amicus to promote GSK oral antibiotics in Serbia and selected GSK respiratory products in Bosnia-Herzegovina. The agreements are effective from October 5th, 2017 for Serbia and from November 1st, 2017 for Bosnia-Herzegovina.

Baar, Switzerland, October 17th, 2017: Amicus S.A. announced today that its Serbian affiliate, Amicus SRB doo of Belgrade, Serbia has entered into a long-term co-promotion agreement with GlaxoSmithkline Export Ltd. of Brentford, UK. Under that agreement, Amicus will provide sales and in-market services to support the established GSK oral antibiotic brands Augmentin, Duac and Zinnat in Serbia. Simultaneously, Amicus's Bosnia affiliate, Amicus Pharma doo Sarajevo signed a separate co-promotion agreement with GSK's Bosnia affiliate, GlaxoSmithkline doo Sarajevo, under which Amicus will provide sales and in-market services to support GSK's novel respiratory products Relvar and Seretide in Bosnia-Herzegovina.

"I am delighted and honoured that Amicus has been offered the opportunity to work with GSK in two countries," commented Predrag Lukic, GM of Amicus Serbia and Regional Director for Albania, Bosnia, Kosovo, Macedonia and Montenegro. We intend to leverage and augment our existing presence with GPs, paediatricians and, in Bosnia, also with respiratory specialists, to support these excellent GSK medicines. We hope to build on the good momentum GSK's local organizations have already created."

About GSK

GSK's pharmaceuticals business discovers, develops and makes medicines to treat a broad range of the world's most common acute and chronic diseases. The business is made up of innovative and established medicines and holds leading positions in respiratory disease and HIV. In our Pharmaceuticals R&D organisation, 80% of research spending focuses on two current therapy areas: respiratory and HIV/infectious diseases; and two potential areas: oncology and immuno-inflammation.

For more information about GSK, please visit <http://www.gsk.com/>; for information on GSK Bosnia please visit <http://www.gsk.com/en-gb/contact-us/worldwide/bosnia-herz>; for information about GSK in Serbia please visit <http://rs.gsk.com/>

About Amicus S.A.

Amicus subsidiaries operate in the Balkan and Baltic countries of Croatia, Estonia, Kosovo, Latvia, Lithuania, Macedonia, Montenegro, Serbia and Slovenia. The company commenced operations in its Hungarian affiliate in July, 2017 and is currently opening affiliates in Albania and Bulgaria. Set up in 2014, Amicus has gathered outstanding pharmaceutical, Medical Device and OTC / consumer healthcare talent. The company specializes in representing research-based pharmaceutical, medical equipment and self-care brands across the Central and Eastern Europe.

For more info about Amicus, please visit: www.amicuspharma.eu

Contact:

Maja Boskovic, Public Affairs Officer, Amicus

Maja.Boskovic@amicuspharma.eu, Tel: +381 11 4426 321